Table 3 Value of the indicators to measure guideline-concordant care in lung cancer patients of the 2007–12 pilot cohort of the Milan province (n = 5746 subjects), overall and in subgroups of patients
| Â | Indicator | Overall | Age class | Gender | Charlson index | Stage | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|  |  | No. | Total No. | % | ≤60 | 61–70 | ≥70 | Male | Female | 0 | 1–2 | ≥3 | I | II | III | IV |
O1 | First contact to first therapy ≤60 days | 1750 | 2663 | 65.7 | 72.1 | 66.4 | 61.8 | 65.2 | 67.4 | 67.9 | 64.0 | 54.5 | 49.1 | 63.9 | 65.1 | 74.3 |
O2 | From PET to surgery ≤45 days | 518 | 706 | 73.4 | 85.0 | 74.3 | 67.1 | 73.9 | 72.0 | 76.0 | 69.7 | 68.4 | 69.9 | 78.4 | 70.4 | 75.4 |
O4 | From thorax CT to surgery ≤45 days | 491 | 759 | 64.7 | 74.5 | 64.6 | 60.5 | 65.5 | 62.6 | 65.5 | 66.4 | 54.2 | 59.6 | 69.2 | 67.3 | 67.5 |
D1 | Thorax CT at diagnosis | 4416 | 5746 | 76.9 | 78.2 | 75.8 | 77.1 | 77.1 | 76.1 | 73.9 | 79.6 | 83.8 | 71.4 | 72.6 | 78.7 | 82.9 |
D2 | Thorax CT before biopsy | 2487 | 3283 | 75.8 | 78.9 | 74.5 | 75.5 | 75.7 | 76.0 | 74.9 | 77.2 | 75.8 | 60.1 | 68.5 | 75.4 | 83.6 |
D3 | Treatment with curative intent preceded by PET | 1098 | 2125 | 51.7 | 48.4 | 42.4 | 57.1 | 51.6 | 51.9 | 48.1 | 52.9 | 62.1 | 42.1 | 40.3 | 57.6 | Â |
D4 | Cyto-histologic confirmation | 4814 | 5746 | 83.8 | 94.1 | 90.5 | 76.6 | 84.3 | 82.2 | 88.1 | 79.7 | 73.5 | 92.6 | 91.6 | 86.6 | 80.5 |
D5 | NSCLC Stage III patients assessed for metastasis before curative intent treatment | 166 | 403 | 41.2 | 48.8 | 40.9 | 37.9 | 42.5 | 37.3 | 43.0 | 39.3 | 34.6 | Â | Â | 41.2 | Â |
D6 | SCLC patients fully staged | 50 | 510 | 9.8 | 10.0 | 14.0 | 6.6 | 8.8 | 12.9 | 12.0 | 6.2 | 8.8 | 16.7 | 0.0 | 12.6 | 8.0 |
S1 | No death after first surgery | 9 | 1124 | 99.2 | 100 | 98.9 | 99.2 | 98.9 | 100 | 99.7 | 98.9 | 96.8 | 100 | 98.7 | 99.4 | 97.1 |
S2 | Patients with a thorax CT ≤30 days before surgery | 330 | 1124 | 29.4 | 34.7 | 31.2 | 25.5 | 30.2 | 27.1 | 28.0 | 31.2 | 31.6 | 24.5 | 33.3 | 28.0 | 39.4 |
S4 | Stage I-IIIA NSCLC patients undergoing surgery with curative intent | 897 | 1768 | 50.7 | 72.9 | 59.6 | 23.7 | 50.1 | 52.4 | 60.5 | 60.0 | 42.1 | 55.4 | 48.3 | 35.8 | Â |
S5 | Stage I-IIA NSCLC patients undergoing lobectomy | 687 | 1005 | 68.4 | 72.5 | 68.8 | 66.4 | 66.6 | 73.2 | 71.2 | 65.0 | 61.4 | 67.7 | 75.1 | 68.2 | Â |
S6 | No second surgery within 30 days | 1117 | 1124 | 99.4 | 99.0 | 99.1 | 99.8 | 99.4 | 99.3 | 99.1 | 99.7 | 100.0 | 99.1 | 100.0 | 99.4 | 100.0 |
S7 | Hospital stay ≤14 days for first surgery | 611 | 930 | 65.7 | 76.5 | 64.8 | 61.9 | 62.3 | 75.1 | 68.6 | 63.3 | 53.3 | 71.7 | 64.6 | 58.6 | 53.5 |
M1 | Stage II-III NSCLC patients receiving chemo-radiation | 46 | 977 | 4.7 | 9.8 | 6.1 | 2.8 | 4.9 | 3.9 | 5.1 | 5.7 | 0.8 | Â | 2.0 | 5.4 | Â |
M2 | SCLC patients undergoing medical oncologic therapy or radiotherapy | 143 | 234 | 61.1 | 75.0 | 65.5 | 53.2 | 59.5 | 65.6 | 65.1 | 60.3 | 46.7 | 50.0 | 56.3 | 65.4 | Â |
M4 | Pain management before death | 4414 | 4798 | 92.0 | 92.1 | 92.2 | 91.8 | 92.4 | 90.7 | 91.0 | 92.8 | 94.3 | 88.8 | 91.2 | 94.1 | 92.1 |
F1 | Follow-up in year 2 for surviving patients | 1122 | 1552 | 72.3 | 69.1 | 74.5 | 71.7 | 72.9 | 70.8 | 70.0 | 76.3 | 73.7 | 71.3 | 70.4 | 82.2 | 74.4 |
| Â | Follow-up in year 3 for surviving patients | 861 | 1169 | 73.7 | 74.2 | 74.7 | 72.4 | 73.9 | 73.2 | 72.0 | 76.9 | 73.8 | 75.3 | 72.4 | 80.9 | 66.1 |
| Â | Follow-up in year 4 for surviving patients | 715 | 892 | 80.2 | 77.5 | 83.2 | 78.2 | 80.2 | 80.0 | 78.8 | 83.3 | 78.9 | 83.5 | 79.6 | 82.3 | 65.0 |